NEW YORK, May 31 - Sangamo Biosciences's acquisition of Gendaq will allow the company to corner the market on zinc finger protein technology as well as to stave off any potential patent disputes, company executives said Thursday.

"Gendaq really represents the one piece of scientific thinking that was not part of our family," Casey Case, Sangamo's vice president for research, told GenomeWeb. "It's great to have them in the fold."

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.